Secondary Logo

Journal Logo

T Follicular Regulatory Cells and Antibody Responses in Transplantation

Wallin, Elizabeth F.1

doi: 10.1097/TP.0000000000002224
Reviews
Free

De novo donor-specific antibody (DSA) formation is a major problem in transplantation, and associated with long-term graft decline and loss as well as sensitization, limiting future transplant options. Forming high-affinity, long-lived antibody responses involves a process called the germinal center (GC) reaction, and requires interaction between several cell types, including GC B cells, T follicular helper (Tfh) and T follicular regulatory (Tfr) cells. T follicular regulatory cells are an essential component of the GC reaction, limiting its size and reducing nonspecific or self-reactive responses.

An imbalance between helper function and regulatory function can lead to excessive antibody production. High proportions of Tfh cells have been associated with DSA formation in transplantation; therefore, Tfr cells are likely to play an important role in limiting DSA production. Understanding the signals that govern Tfr cell development and the balance between helper and regulatory function within the GC is key to understanding how these cells might be manipulated to reduce the risk of DSA development.

This review discusses the development and function of Tfr cells and their relevance to transplantation. In particular how current and future immunosuppressive strategies might allow us to skew the ratio between Tfr and Tfh cells to increase or decrease the risk of de novo DSA formation.

A comprehensive review by Wallin et al on T follicular regulatory T cell development, as well as their ability to control germinal center B cell responses and subsequent DSA production.

1 Transplant Research Immunology Group, Nuffield Department of Surgical Sciences, Level 6 John Radcliffe Hospital, Oxford.

Received 2 December 2017. Revision received 7 March 2018.

Accepted 9 March 2018.

E.F.W. was supported by a Kidney Research UK/MRC Clinical Fellowship.

The author declares no conflict of interest.

Correspondence: Elizabeth F. Wallin, Transplant Research Immunology Group, Nuffield Dept Surgical Sciences, Level 6 John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom. (lizwallin@doctors.org.uk).

In the current era of transplantation, short-term outcomes are excellent.1 However, long-term graft attrition has remained relatively unchanged over the past few decades,2-4 with a steady decline and rate of loss after the first year posttransplant1 that has not improved despite improvements in organ retrieval, organ allocation, and immunosuppressive regimens.1,5-7 There is increasing evidence that chronic rejection, associated with and potentially mediated by antibodies,8-10 is a major cause of long term graft loss.11-13 In kidney transplantation, 8% to 10% of recipients develop de novo donor-specific anti-HLA antibodies (DSA) within the first year,14,15 and between 15% and 30% within 10 years.10,16,17 These antibodies are associated with an increased risk of graft failure8,10,18,19 and therefore the cells that interact to produce alloantibody are becoming increasingly recognized as important targets in transplantation to try to improve long-term outcomes.20,21

Many researchers have looked at the cells involved in the development of antibody responses against transplanted tissue, in particular T follicular helper (Tfh) and germinal center (GC) B cells. These studies have previously been comprehensively reviewed22,23; however, control of the GC reaction is provided by a specialized subset of regulatory T (Treg) cells known as T follicular regulatory (Tfr) cells. This review summarizes the current literature on Tfr cells and their relevance to transplantation, including how we might manipulate them to alter antibody responses to transplanted tissue.

Back to Top | Article Outline

THE GC REACTION

To produce long-lived, high-affinity antibody responses, mature naïve B cells must enter the B cell follicle of secondary lymphoid organs (SLOs) and interact with T cells in a process called the GC reaction.24

Anti-HLA antibodies, and particularly posttransplant DSA, are predominately class switched,25-29 and persist in the circulation for many years both pre and posttransplant, suggesting that they have been produced by plasma cells that have come from the GC.30-32 HLA-specific B cells with memory markers (CD27, CD28) have also been identified in the circulation,33-35 and HLA-specific plasma cells in the bone marrow30 of transplant patients, suggesting a requirement for GC formation, and hence for T-cell help,36 in the development of a response to the transplanted organ.34 Animal models have supported this, showing that antibody-mediated rejection is T cell–dependent.37-41 Studies in humans have been more limited because of the difficulty of obtaining secondary lymphoid tissue, but kidneys were removed after rejection have shown evidence of somatic hypermutation (SHM) in intragraft B-cell aggregates.42 It is therefore likely that the GC reaction is necessary for the development of anti-HLA antibodies and particularly DSAs.

The GC reaction is a process that allows generation of a broad spectrum of highly specific, high-affinity antibodies to provide protection against the multiple pathogens that are encountered over the lifetime of an individual.24 Over the course of an antibody response, for example, to vaccination, the affinity of antibodies for antigen increases in a process known as affinity maturation.43,44 To increase affinity, proliferating GC B cells undergo SHM45,46 of their B-cell receptor (BCR) genes. However, random mutation may generate BCRs with both lower and higher affinity for antigen, as well as potentially self-reactive BCRs.47 To ensure that only higher-affinity B cells go on to produce antibodies, which are soluble forms of the BCR, a selection process takes place within the GC that is dependent on T cells.22,23 T-cell help comes from Tfh cells, CD4 T cells that have downregulated CCR7, the chemokine receptor that directs them to the T-cell zone of SLOs, and upregulated CXCR5, the chemokine receptor that traffics cells to the B-cell zone. After entering the follicle, Tfh cells are key players in the maintenance of the GC response, and selection of GC B cells, with GCs collapsing in the absence of Tfh cells.48 Tfh cells contain preformed CD40L that can be rapidly expressed on the cell surface to provide CD40 signaling to GC B cells during cognate T:B interactions.49,50 Tfh cells can also provide help in the form of cytokines. IL-21 is the classical cytokine associated with Tfh cells, maintaining Bcl6 expression in GC B cells and stimulating plasma blast development.51-54 It is thought that B cells with higher BCRs can take up more antigen from follicular dendritic cells and outcompete lower-affinity B cells for T-cell help,55 hence, lower-affinity B cells either do not receive CD40L signaling and undergo apoptosis, or receive signals to induce reentry into cell cycle and further rounds of SHM.56 This would allow only the higher affinity cells to differentiate into long-lived memory B cells or plasma cells that then migrate to bone marrow or gut niches to form long-lived plasma cells.57 However, in the presence of excessive Tfh cells, lower-affinity or self-reactive B cells can receive help.58-60 Thus, control of the GC reaction is essential and is thought to both reduce the likelihood of autoantibodies and potentially ensure higher-affinity antibody production. Tfr cells are a subset of Treg cells that have co-opted the Tfh pathway to upregulate CXCR5 and enter the GC (Figure 1) to provide regulation of GC responses.

FIGURE 1

FIGURE 1

Cells with regulatory properties have long been of interest in transplantation because it was hoped that they might be the key to immunological tolerance to the transplanted organ without compromising protective immunity. Much research has been done looking at CD4+ Treg cells in particular and their potential use in tolerogenic immunosuppressive strategies, summarized by Wood and Sakaguchi.61 Both animal models and human studies have lead to clinical trials in autoimmune disease and now transplantation. The recently completed ONE study (http://www.onestudy.org/) has used several regulatory cell types in kidney transplantation in an attempt to induce tolerance to a transplanted organ,62,63 and detailed results are awaited.

However, Treg cells are a diverse group of cells containing many subsets designed to regulate a range of immune responses. Treg cells act through a number of mechanisms, including anti-inflammatory cytokines, such as IL-10 and TGFβ, as well as cell contact–dependent inhibition of T-cell activation by inhibitory receptors, such as CTLA-4 (CD152). In addition, Treg cells can express transcription factors traditionally associated with other Th subsets alongside Foxp3 and tailor their suppression to the response generated.64-66 It is not surprising therefore that Treg cells can also co-opt the Tfh pathway, expressing Bcl6 alongside Foxp3, and upregulating surface markers associated with Tfh, such as CXCR5, ICOS, and PD-167-69 to enter the GC as Tfr cells.

Back to Top | Article Outline

Tfr CELL DEVELOPMENT

Although the presence of regulatory cells in SLOs and in the GC has long been established,68,70 the first detailed description of Tfr cells, Treg cells that could enter the B-cell follicle and control the production of antibody, occurred in 2011. Two groups simultaneously described Tfr cells,67,71 and their findings were confirmed by a third group.69 Under these experimental conditions, Tfr cells were derived from thymic precursors and expressed Foxp3 alongside Bcl6 and Blimp1.67,69,71 The latter was of particular interest, as Bcl6 and Blimp1 are mutually antagonistic, but Linterman et al67 showed that the dynamic expression of these transcription factors was required, with Bcl6 required for the development of the follicular phenotype in Treg cells and Blimp1 required to limit the size of the Tfr population.

In a similar way to Tfh cells, Tfr cells seem to require initial priming by dendritic cell (DCs)72,73; however, unlike Tfh cells, which require achaete-scute homologue-2 for expression of CXCR5 and inhibition of Th1 and Th17 pathways,74 Tfr cells seem to be more dependent on nuclear factor of activated T cells (NFAT)-2 for initiation of CXCR5 expression.75 Both Tfh and Tfr cells are highly dependent on NFAT signaling75-77 which is of interest in transplantation as calcineurin activation dephosphorylates NFAT and allows it to translate to the nucleus,78 meaning calcineurin inhibitors (CNIs) may inhibit Tfh and Tfr cell differentiation to a greater extent than other T-cell subsets.

Upregulation of CXCR5 following priming by DCs allows both pre-Tfh and pre-Tfr to migrate toward the T-B border.56,73 In a similar way to Tfh, Tfr cells can then either exit the SLO into the circulation as memory-like circulating Tfr (cTfr) cells with lower expression of ICOS and PD-1 (discussed below), or move into the B cell follicle to regulate the GC response.73 Much like Tfh cells, Tfr cells are dependent on signaling via the T-cell receptor (TCR) as well as costimulation,67,79,80 and both CD28 and ICOS are essential costimulatory molecules for Tfr development,67,80,81 as cd28−/− and icos−/− mice lack Tfr cells.

Interestingly, in the absence of B cells, cTfr cells can be found but Tfr cells in SLOs are absent,73 suggesting that interactions with DCs are sufficient for initiation of the Tfr pathway, but interactions with B cells, whether at the T-B border before entry into the follicle or in the follicle itself, are required for pre-Tfr to differentiate into Tfr cells and gain full suppressive capacity.73 There is debate as to the location of B-cell interaction in part because it is not clear if Tfr cells are specific for the immunizing antigen and could in fact develop from naive T cells via interaction with antigen-specific B cells under certain circumstances82 or have a TCR repertoire more similar to Treg cells, developing in a non–antigen-specific way.83

This distinction is likely to be extremely important in the context of transplantation, particularly in the era of regulatory cell therapies. If antigen-specific Tfr cells could reduce the development of antigen-specific antibodies, then altering the ratio of antigen-specific Tfh and Tfr may help to prevent the development of DSAs without limiting the development of antibodies against other antigens, such as bacterial antigens. If this could be managed, it may fulfil the elusive goal of transplant tolerance without compromising protective immunity. Aloulou et al82 showed that Tfr cells in the lymph node (LN) could develop from induced Treg cells and be specific for the antigen as long as the stimulus was one that would normally generate induced Treg cells. However, if the antigen was foreign rather than self, they demonstrated that the balance was shifted toward antigen-specific Tfh cells, rather than Tfr cells, which predominated when immunization was with self-antigen.82

In the context of transplantation, the inflammatory insult of surgery and ischemia-reperfusion injury5,84 around transplantation and the presence of nonself antigen would be likely to promote antibody formation a high Tfh to Tfr ratio among antigen-specific cells82; however, there is the potential for manipulation of this system, either by depleting or blocking Tfh cells85,86 or possibly by promoting the development of Tfr cells.

The discovery that induced Treg cells are capable of developing into antigen-specific Tfr cells82 could potentially allow ex vivo generation of antigen-specific Treg cells, rather than polyclonal Treg cells, which are currently being generated by the ONE study.87 If these cells could be induced to form donor-antigen-specific Tfr cells, perhaps through PD-L1 stimulation as shown by this group,82 this could potentially allow reduction in the development of de novo DSAs. If this were possible, it would presumably limit therapy to those with a live donor, as the generation of polyclonal Treg cells currently takes around 14 days.87 Given that generation of antigen-specific Tfh and Tfr cells begins within 48 hours of an immunizing event,74,82 allospecific Tfr cells would need to be introduced very early posttransplant, meaning only those with planned surgical dates could have allospecific cells generated ex vivo to avoid prolonged cold storage. However, these data are exciting and may support currently proposed strategies to move from polyclonal Treg cells therapy to allospecific Treg cells therapy,88,89 allowing not just allospecific Treg cells, but also allospecific Tfr to be generated.

Further work is required to determine if these antigen-specific Tfr cells are short lived or capable of forming long-lived memory responses. It would be of interest to know if antigen-specific Tfr cells can be seen in the circulation following immunization, as circulating Tfr cells are thought to represent a memory population.73 The requirement for lifelong acceptance of the transplanted organ in the presence of other inflammatory insults such as cellular rejection episodes; infections and future surgical insults would mean that a short-lived response would be of limited benefit to transplant recipients.

It may be of more use to understand the factors that may drive development of antigen-specific Tfr. Manipulation of antigen presenting cells to shift the balance of responding cells from a proinflammatory to a tolerogenic profile is currently being trialled in transplantation.90,91 As Tfr cells are also dependent on the signals from DCs to develop, using antigen-specific DCs expressing high levels of PD-L1 may be able to drive antigen-specific Tfr development to reduce GC responses to a particular antigen.82 Manipulation of these pathways is currently being explored with the aim of improving vaccination responses (multiple animal studies, reviewed by Linterman and Hill92). However considerable work is required to refine our understanding of the pathways that both enhance and inhibit Tfr cell development and how we might safely manipulate them to improve or inhibit GC responses.

At present, several molecules are known to inhibit Tfr cell development, including CTLA4 (discussed below), PD-1 and IL-2. PD-1 is an inhibitory receptor of great interest in the field of autoimmunity,93-96 cancer97 and vaccination98 and is a key marker of Tfh and Tfr cells.99,100 PD-1 and its ligand PD-L1 are important for the induction and maintenance of induced Treg cells and in the absence of PD-L1 signaling, induction of Treg cells from naive CD4 T cells is much lower.101 In contrast, although it is not entirely clear what the function of PD-1 on Tfh and Tfr cells is, it appears to have an inhibitory role. In pdcd1−/− mice, Tfr cells are seen in greater proportion in the LN and blood, whereas Tfh cells are seen in greater proportion in the blood, but reduced in the LN, consistent with the greater suppressive capacity of LN Tfr cells compared to cTfr cells.80 It is not clear how PD-1 signaling curtails Tfh or Tfr function, or why it is expressed so highly on Tfh and Tfr cells. However, the authors of this article speculate that, as strong TCR signaling slows T-cell movement, PD-1 may reduce the strength of the signal and allow Tfh cells to scan more B cells, giving help only to the highest affinity cells which would elicit the strongest TCR signal.

Interestingly, Aloulou et al82 showed that antigen-specific Tfr cells required PD-L1 signaling to develop, this may be due to the fact that these cells develop from induced Treg cells, rather than natural Treg cells, and thus are highly dependent on PD-L1 signaling for precursor development.101 Further signals that promote conversion of induced Treg cells to Tfr cells are yet to be elucidated, and it is not clear if they would follow the same pathway of development, and require the same DC and B cell interactions as Tfr cells derived from thymic precursors.

It is also of interest that Treg cells are highly dependent on IL-2 signaling102,103 and yet this cytokine suppresses Tfh and Tfr cell responses.104,105 Botta et al106 showed that at the peak of influenza infection, the high levels of IL-2 promoted Blimp-1 expression in Treg cells, which prevented Bcl6 upregulation and hence prevented them developing into Tfr cells. As the infection cleared and IL-2 levels fell, a proportion of Treg cells downregulated CD25, upregulated Bcl6 and took on a Tfr phenotype. This allows early initiation of an antibody response, as high Treg cell consumption of IL-2 is thought to permit Tfh cell development,107 but then curtailing of this response after the infection is cleared, to prevent uncontrolled GC responses leading to autoantibody production.

The dynamic regulation of Tfr cell activation and maturation is a key factor in developing an effective humoral immune response. At a resting state, animal models suggest that, although Tfr cells are a rare population (approximately 1% of the total CD4 T cell population in mice) depending on the tissue studied, in the B-cell follicle, they can be at equal proportion to Tfh cells.73,80,108 During the course of an immune response, both Tfh and Tfr cells begin to proliferate; however, Tfh cells proliferate faster and skew the proportion in favor of helper capacity. By day 7, the peak Tfh response and when GCs begin to form,56,109 Tfr cells represent less than 20% of the follicular CD4 T cell population,80 but by day 10 Tfh numbers have started to fall while Tfr cell proliferation continues, and so ratio returns to the resting state.80 In tissues exposed to constant antigen stimulation, the ratio of Tfr to Tfh cells is lower, for example, Peyer patches where constant IgA production is required,110 and the spleen, where rapid responses to blood borne antigens are essential.111 The ratio of Tfr to Tfh cells is not only important for the control of normal immune responses, but also to limit autoimmunity, as uncontrolled Tfh responses lead to spontaneous autoimmunity.58,60 Understanding more about how this process is controlled and the interplay between different cell types and signaling pathways is important to identify targets that might allow us to manipulate this process.

Back to Top | Article Outline

BIOMARKERS OF GC RESPONSES

Many studies of human disease have used circulating Tfh-like cells (cTfh) and circulating Tfr-like cells (cTfr) as biomarkers looking at both normal antigen responses in vaccination112,113 and abnormal responses in autoimmune disease and chronic viral infection. Studies after influenza vaccination demonstrate the potential use of cTfh cells as a peripheral biomarker of GC activity. After vaccination, subjects showed increased ICOS+PD-1+CXCR3+CXCR5+CD4+ Tfh cells at 7 days, which correlated both with plasmablast appearance in the circulation and development of strain-specific influenza antibody.113 However, these studies did not look at Tfr markers to separate helper from regulatory cells. Animal models have suggested that cTfr cells, circulating cells resembling LN Tfr cells, also represent a memory population73 and are reflective of an ongoing GC response. As secondary lymphoid tissue is difficult to obtain in humans, it is important to elucidate how closely the ratio of circulating cells reflects the tissue resident populations. This has been most closely investigated in autoimmune disease and chronic viral infection.

In human autoimmune disease, circulating Tfh and Tfr cells have been reported in many different conditions. It was originally suggested that high proportions of cTfh cells correlated with autoantibody levels in many diseases114-118; however, many of these early studies did not differentiate between Foxp3+ and Foxp3 cells in the circulation, describing whole populations of CD4+CXCR5+ cells with the addition of PD-1 or ICOS as markers of Tfh-like cells. Further studies have looked specifically at cTfr levels and ratios, but reports have been variable, with some studies showing higher percentages of cTfr cells in certain autoimmune diseases,119 whereas others demonstrated lower levels120 with a skew toward high cTfh cells. In all studies, higher proportions of circulating cells of both types seem to correlate with active inflammation and antibody production. However, extensive animal work suggests that uncontrolled Tfh cell responses lead to autoimmunity,58-60 combining this with the human studies suggesting high cTfh cells correlate with active disease and high autoantibody levels,118,121 it would seem likely that uncontrolled Tfh responses in humans are also associated with autoimmunity. It is not yet clear whether these are due to ineffective Tfr responses, or whether the breakdown in self-tolerance is the key factor that allows a persistent antibody response, driving the immune system toward Tfh-mediated antibody production and suppressing Tfr responses to a mistaken “nonself” antigen.82

In the absence of a breakdown in self-tolerance, the ratio of cTfh to cTfr seems to be important in driving antibody formation. In chronic viral infection higher levels of cTfr correlated positively with higher levels of hepatitis B or C viral deoxyribonucleic acid,122 suggesting that in the presence of chronic antigen stimulation, having higher levels of Tfr cells prevents the formation of antibodies that might help clear the infection. In human immunodeficiency virus, ineffective Tfh responses and excessive Tfr responses are thought to prevent the development of bnAbs,123-126 allowing persistence of the virus due to inadequate GC responses. Indeed human immunodeficiency virus+ patients show inadequate responses to vaccination, suggesting a generalized defect in GC responses, not specific to the virus.125,127,128 The balance between Tfh and Tfr responses is therefore finely tuned and likely to be a key factor in the development of antibodies to persistent antigens.

In transplantation, this balance may also be important, as, like a chronic virus, the transplanted tissue provides a persistent antigenic stimulation that cannot easily be cleared. However, studies of cTfh and cTfr cells have been limited. Some human observational studies have suggested that high levels of cTfh correlate with DSA production, and low levels of cTfr cells correlate with chronic rejection.86,129-131 This is in keeping with animal models showing that Tfh cells are required for DSA formation38 and blocking pathways important for GC development reduces DSA levels.132 The data on Tfr cells in transplantation is even more limited. In graft-versus-host disease (GVHD), a complication of hematopoietic stem cell transplantation where repopulating cells see the recipient tissues as nonself and therefore mount a response, low levels of Treg cells are associated with worse disease.133 Additionally, Tfh cells seem to be important in driving chronic GVHD, as transplantation of CXCR5-deficient T cells showed attenuated disease, as did blocking IL-21, ICOS and CD40.134 McDonald-Hyman et al showed that infusion of Treg cells before hematopoietic stem cell transplantation or after established GVHD led to attenuation of disease, and this was thought, in part, to be mediated by an increase in Tfr cells limiting Tfh cells and antibody production.135 Whether this finding also holds true in solid organ transplant is yet to be elucidated. However, animal models have shown that Treg cells increase in protocols designed to induce transplant tolerance136 and Treg cells are higher in patients who are operationally tolerant of their grafts,137,138 cTfh cells have also been shown to be lower in operationally tolerant renal transplant recipients139 suggesting that the balance between follicular effector and regulatory cells is important for tolerance to transplanted antigens.

Back to Top | Article Outline

IMPACT OF IMMUNOSUPPRESSION ON TFR CELLS

Although an antibody response to donor antigen is a normal response to nonself, and therefore a skew in favor of Tfh cells would be expected early posttransplant, many of the immunosuppressive agents are T cell targeted and may interfere with the normal process of dynamic regulation.

Commonly used induction strategies include blockade of CD25, the alpha chain of the IL-2 receptor, with agents, such as basiliximab, and lymphocyte depletion with agents, such as ATG and alemtuzumab. Blockade of CD25 is designed to prevent activation of T cells, in part by blocking autocrine production of IL-2, limiting the levels of this cytokine. Lower levels of IL-2 would prevent IL-2–mediated upregulation of STAT5, thus preventing STAT5-dependent blockade of Bcl6 upregulation.104 This would be permissive of Tfh cell development, but the lack of IL-2 signaling would also allow Treg cells to upregulate Bcl6 and develop into Tfr cells and potentially promote Tfr cell development over Tfh cells.106 However, given Treg cells are highly dependent on IL-2 signaling and Tfr are thought to develop from nTreg cells, it may also reduce Tfr numbers by reducing precursor cells. Therefore, it is not clear whether induction therapy with basiliximab or other CD25 blocking mAbs would lead to a balanced increase in both Tfh and Tfr cells, or whether there is a skew toward regulatory or helper function. Although in wide use, it is also not clear from epidemiological studies if anti-CD25 mAbs alter the risk of de novo DSA formation compared with alternative induction methods.140 Further observational studies with immunophenotyping of recipients would be useful to establish the effect of both induction and maintenance therapy on the ratio of Tfh to Tfr cells, and further elucidate the relative risk of de novo DSA formation.

The impact of lymphocyte depleting agents is another unknown, in part due to the complexity of the recovering cell population dynamics. Alemtuzumab, another widely used induction agent, leads to widespread lymphocyte depletion with variable recovery, however from phenotyping studies in autoimmunity, it appears to increase the proportion of Treg cells in the recovering CD4 T cell population.141,142 Given the evidence suggesting Tfr cells can develop from induced Treg cells, alemtuzumab induction may skew the balance in favor of Tfr responses when the proinflammatory milieu (and hence IL-2 levels) has reduced. However, autoimmunity following alemtuzumab, which occurs in up to a third of multiple sclerosis patients treated with the drug, has been shown to be IL-21–dependent143 therefore suggesting that the increase in the proportion of Treg cells, which will consume IL-2 and therefore allow Tfh cell development, may skew the balance towards helper function rather than regulation. More work is required to understand the impact of these agents on the cells that interact to form antibodies.

Current maintenance immunosuppressive agents tend to target T cell pathways, and hence may affect both Tfh and Tfr cells. Tfh and Tfr cells are both highly dependent on NFAT signaling,75,77 which is itself dependent on calcineurin dephosphorylation, hence disruption by CNIs may affect these cells more than other cell subsets. Additionally, mammalian target of rapamycin (MTOR)C1 has been found to promote the generation of Tfr cells and be important for suppressive function,76,144 so use of MTOR inhibitors may adversely affect Tfr cell function, skewing the balance towards Tfh cells. This is supported by animal models suggesting that the use of MTOR inhibitor rapamycin (sirolimus) after alemtuzumab induction increases the proportion of Tfh cells and consequently of DSAs.145 Given the complexity of the pathways that interact to generate a GC response, it would be prudent to understand these pathways and the influence of drugs before targeting the GC response to either promote or reduce antibody responses.

An example of unintentional manipulation of the GC response has recently been demonstrated. Costimulatory blockade using belatacept, a CTLA-4/IgG1 fusion protein, has been approved for use in transplantation as an alternative maintenance agent for those unable to tolerate CNIs or where CNI toxicity has been demonstrated. CTLA-4 is an inhibitory receptor with a much higher affinity for CD80/86 than CD28, its stimulatory counterpart, and is an important mechanism of Treg cell–mediated suppression through disruption of CD28-CD80/86 signaling.146,147

Although this is a key mechanism of Treg cell–mediated suppression, it is not clear how Tfr cells suppress GC responses. For example, IL-10, a key anti-inflammatory cytokine produced by Treg cells148 and Tfr cells (and possibly Tfh cells73), appears to have a role in supporting GC B cell survival149 and maintaining normal light zone/dark zone differentiation.150 The function of CTLA-4 on Tfr cells is also unclear. Although germline deletion of CTLA-4 in mice is fatal in early life due to overwhelming autoimmunity and autoantibody formation,151,152 and in humans mutations in CTLA-4 leads to profound immune dysregulation,153 blockade or deletion of CTLA-4 later in life does not cause these issues and may even be protective against certain forms of autoimmunity by increasing IL-10 production.154 In animal models, Treg cell–specific deletion of CTLA-4 leads to a significant increase in Tfr cell numbers in SLOs and of cTfr cells in the circulation,147,155 suggesting a directly inhibitory effect on Tfr cells. However, although Tfr numbers may be increased, these cells show reduced suppressive capacity in vitro,147,155 suggesting it is a key molecule for Tfr function. Interestingly in 1 study, whereas mice with CTLA-4 deficient Tfr cells had higher numbers of Tfh cells and higher antibody level, this was of lower affinity, with the authors postulating that suppression by Tfr cells may reduce the amount, but increase the affinity of antibody produced by ensuring only B cells with the highest affinity for antigen go on to receive T-cell help and develop into plasma cells.155

In humans, CTLA-4 Ig has been widely used as a treatment for autoimmune disease and as maintenance therapy in transplantation in an attempt to mimic its function on Treg cells.132,156-158 It has good efficacy compared with CNIs, with an increased rate of acute rejection early post transplant but improved long-term outcomes.159 Interestingly, belatacept has been linked to smaller GC responses, lower levels of Tfh in LN and a lower rate of DSA formation in a non-human primate model.132 Additionally, mouse models show CTLA-4Ig can suppress both de novo and memory DSA responses by reducing Tfh numbers.160 This is supported by data from the BENEFIT-EXT trial showing a markedly reduced rate of DSA formation with belatacept treatment compared to ciclosporin.161 These studies support the idea that inhibition through CTLA-4 is one of the key factors in Tfr-mediated suppression of GC responses; however, exactly how this is mediated is unclear. Interestingly in vitro work by this same group suggests that this is not due to a direct effect of CTLA-4Ig on Tfh cells or their interactions with B cells.162 These apparently conflicting results require further investigation, and it would be of interest to see long-term phenotyping studies on samples from patients receiving belatacept maintenance therapy to see whether the ratio of cTfr to cTfh cells, or the function of these cells changes over time, as the improved outcomes from belatacept compared with CNIs tend to manifest later posttransplant.

Another trial of great interest will be the ONE study. With the advent of cell therapy, multiple regulatory cell populations have been generated ex vivo and infused into patients undergoing living donor transplantation. Multiple sites have been set up, with different sites investigating the safety and feasibility of using different cell subsets, ranging from regulatory T cells to tolerogenic DCs and suppressive macrophage subsets. Standardized immunophenotyping has been undertaken for all patient groups in order to examine the effects of different cell therapies on the circulating immune profile.163 Unfortunately these standardized panels do not include cTfh or cTfr markers, so it is unclear if there will be any impact of cell therapy on GC activity. It will be of interest to see whether therapy with polyclonal induced Treg cells will lead to any alterations in the rate of de novo DSA formation. Given the animal data suggesting that Tfr can develop both from thymic and induced Treg cells, it is possible that infused Treg cells could also take on a Tfr phenotype and provide suppression of GC responses. However, the excess consumption of IL-2 from an infusion of Treg cells may allow differentiation of Tfh cells and thus increase the likelihood of DSA development, although it is unclear how much impact CNI maintenance therapy, which is given alongside Treg cells, may affect the cell populations. Additionally, there is concern that the infused Treg cells may not be stable, and in the context of inflammatory stimuli, such as infection, operative intervention, or indeed acute rejection, could potentially convert to other helper cell phenotypes.164 These early studies will hopefully provide some answers and guide future investigations.

Back to Top | Article Outline

FUTURE DIRECTIONS

Although it is clear that Tfh cells must play a role in alloantibody formation38,86,131 it is not yet clear what the role of Tfr cells is in modulating alloantibody formation. Inhibition of Tfr cell function through conditional deletion of CTLA-4 leads to more but lower affinity antibodies.155 One of the postulated roles of Tfr cells is to prevent antibody responses in the context of low levels of antigen73 or where B cells have only generated low-affinity receptors through SHM.67,71 Paradoxically, it may therefore be that a skew toward Tfr responses leads to fewer, but higher affinity DSAs that are more likely to lead to rejection. Alternatively, given the persistence of antigen, the potential need for manipulation to increase the ratio of Tfr to Tfh cells long term may limit antibody formation in all areas, both to donor antigens and to pathogens, thus increasing the risk of infection.

Until a mechanism can be found to selectively enhance and maintain the development of antigen-specific Tfr cells to reduce the production of clinically undesirable antibodies, such as DSAs, without reducing production of helpful antibodies, altering the ratio of Tfr to Tfh cells where there is long-term exposure to and persistence of nonself antigen may not be a feasible approach to reduce the risk of DSA formation.

It seems we may inadvertently have stumbled upon one such manipulation strategy with the use of belatacept, although further work is required to establish the exact mechanism of action and if this is mediated through GC responses or other pathways.

In summary, the GC response and roles of Tfh and Tfr cells are at the forefront of immunological research, and understanding the regulation of the GC and antibody production is essential as the field of transplantation medicine moves forward. Tackling de novo DSA formation is one of the key targets for improving transplant longevity and reducing waiting times for those who are sensitized. Understanding how the GC response changes posttransplant using the biomarkers of cTfh and cTfr is important in understanding and predicting those at risk of de novo DSA formation. Additionally, understanding how different immunosuppressive regimens and strategies influence humoral immunity will be key to finding treatment options for these patients. There are many questions still to be answered, but with new scientific tools and comprehensive phenotyping panels, marrying high-quality bench science with clinical trial protocols can provide answers to at least some of these questions.

Back to Top | Article Outline

REFERENCES

1. NHSBT-ODT. Survival Rates Following Transplantation. Section 11. http://www.odt.nhs.uk/uk-transplant-registry/annual-activity-report/. 2016.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4:1289–1295.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378–383.
4. Walsh L, Dinavahi R. Current unmet needs in renal transplantation: a review of challenges and therapeutics. Front Biosci (Elite Ed). 2016;8:1–14.
5. Johnson RJ, Fuggle SV, O'Neill J, et al. Factors influencing outcome after deceased heart beating donor kidney transplantation in the United Kingdom: an evidence base for a new national kidney allocation policy. Transplantation. 2010;89:379–386.
6. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350:1193–1198.
7. NHSBT-ODT. Selection Policy for Kidney Transplantation. http://www.odt.nhs.uk/information-for-patients/kidney/. 2016.
8. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8:348–357.
9. Hirai T, Kohei N, Omoto K, et al. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int. 2012;25:925–934.
10. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9:2532–2541.
11. Chand S, Atkinson D, Collins C, et al. The spectrum of renal allograft failure. PLoS One. 2016;11:e0162278.
12. Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17:28–41.
13. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–283.
14. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95:410–417.
15. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13:1541–1548.
16. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–1167.
17. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000;69:319–326.
18. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9:2520–2531.
19. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399.
20. Baan CC. Basic sciences in development: what changes will we see in transplantation in the next 5 years? Transplantation. 2016;100:2507–2511.
21. Metes DM. T follicular helper cells in transplantation: specialized helpers turned rogue. Transplantation. 2016;100:1603–1604.
22. Kwun J, Manook M, Page E, et al. Crosstalk between T and B cells in the germinal center after transplantation. Transplantation. 2017;101:704–712.
23. Walters GD, Vinuesa CG. T follicular helper cells in transplantation. Transplantation. 2016;100:1650–1655.
24. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–457.
25. Cicciarelli JC, Kasahara N, Lemp NA, et al. Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients. Clin Transpl. 2013:413–422.
26. Griffiths EJ, Nelson RE, Dupont PJ, et al. Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation. 2004;77:1771–1773.
27. Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant. 2007;7:1808–1814.
28. Lietz K, John R, Burke E, et al. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation. 2005;112:2468–2476.
29. Khovanova N, Daga S, Shaikhina T, et al. Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. Transpl Int. 2015;28:1405–1415.
30. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant. 2008;8:133–143.
31. Regan L, Braude PR, Hill DP. A prospective study of the incidence, time of appearance and significance of anti-paternal lymphocytotoxic antibodies in human pregnancy. Hum Reprod. 1991;6:294–298.
32. van Kampen CA, Versteeg-vd Voort Maarschalk MF, Langerak-Langerak J, et al. Claas FH kinetics of the pregnancy-induced humoral and cellular immune response against the paternal HLA class I antigens of the child. Hum Immunol. 2002;63:452–458.
33. Heidt S, Roelen DL, de Vaal YJ, et al. A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals. Am J Transplant. 2012;12:1469–1478.
34. Zachary AA, Kopchaliiska D, Montgomery RA, et al. HLA-specific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation. 2007;83:982–988.
35. Lynch RJ, Silva IA, Chen BJ, et al. Cryptic B cell response to renal transplantation. Am J Transplant. 2013;13:1713–1723.
36. Steele DJ, Laufer TM, Smiley ST, et al. Two levels of help for B cell alloantibody production. J Exp Med. 1996;183:699–703.
37. Pettigrew GJ, Lovegrove E, Bradley JA, et al. Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts. J Immunol. 1998;161:1292–1298.
38. Conlon TM, Saeb-Parsy K, Cole JL, et al. Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. J Immunol. 2012;188:2643–2652.
39. Callaghan CJ, Rouhani FJ, Negus MC, et al. Abrogation of antibody-mediated allograft rejection by regulatory CD4 T cells with indirect allospecificity. J Immunol. 2007;178:2221–2228.
40. Bradley JA, Mowat AM, Bolton EM. Processed MHC class I alloantigen as the stimulus for CD4+ T-cell dependent antibody-mediated graft rejection. Immunol Today. 1992;13:434–438.
41. Nakanishi T, Xu X, Wynn C, et al. Absence of activation-induced cytidine deaminase, a regulator of class switch recombination and hypermutation in B cells, suppresses aorta allograft vasculopathy in mice. Transplantation. 2015;99:1598–1605.
42. Ferdman J, Porcheray F, Gao B, et al. Expansion and somatic hypermutation of B-cell clones in rejected human kidney grafts. Transplantation. 2014;98:766–772.
43. Jerne NK. A study of avidity based on rabbit skin responses to diphtheria toxin-antitoxin mixtures. Acta pathologica et microbiologica Scandinavica. Supplementum. 1951;87:1–183.
44. Eisen HN, Siskind GW. Variations in affinities of antibodies during the immune response. Biochemistry. 1964;3:996–1008.
45. Weigert MG, Cesari IM, Yonkovich SJ, et al. Variability in the lambda light chain sequences of mouse antibody. Nature. 1970;228:1045–1047.
46. McKean D, Huppi K, Bell M, et al. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 1984;81:3180–3184.
47. Guo W, Smith D, Aviszus K, et al. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J Exp Med. 2010;207:2225–2237.
48. Vinuesa CGd, Cook MC, Ball J, et al. Germinal centers without T cells. J Exp Med. 2000;191:485–493.
49. Casamayor-Palleja M, Khan M, MacLennan IC. A subset of CD4 + memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med. 1995;181:1293–1301.
50. Shulman Z, Gitlin AD, Weinstein JS, et al. Dynamic signaling by T follicular helper cells during germinal center B cell selection. Science. 2014;345:1058–1062.
51. Zotos D, Coquet JM, Zhang Y, et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med. 2010;207:365–378.
52. Linterman MA, Beaton L, Yu D, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med. 2010;207:353–363.
53. Vogelzang A, McGuire HM, Yu D, et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity. 2008;29:127–137.
54. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science. 2002;298:1630–1634.
55. Victora GD, Schwickert TA, Fooksman DR, et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell. 2010;143:592–605.
56. Vinuesa CG, Linterman MA, Goodnow CC, et al. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev. 2010;237:72–89.
57. Clatworthy MR, Espeli M, Torpey N, et al. The generation and maintenance of serum alloantibody. Curr Opin Immunol. 2010;22:669–681.
58. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005;435:452–458.
59. Pratama A, Ramiscal RR, Silva DG, et al. Roquin-2 shares functions with its paralog Roquin-1 in the repression of mRNAs controlling T follicular helper cells and systemic inflammation. Immunity. 2013;38:669–680.
60. Linterman MA, Rigby RJ, Wong RK, et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med. 2009;206:561–576.
61. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3:199–210.
62. van der Net JB, Bushell A, Wood KJ, et al. Regulatory T cells: first steps of clinical application in solid organ transplantation. Transpl Int. 2016;29:3–11.
63. Juvet SC, Whatcott AG, Bushell AR, et al. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant. 2014;14:750–763.
64. Koch MA, Tucker-Heard G, Perdue NR, et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595–602.
65. Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009;326:986–991.
66. Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–356.
67. Linterman M, Pierson W, Lee S, et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med. 2011;17:975–982.
68. Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell–driven B cell responses. J Clin Invest. 2004;114:1640–1649.
69. Wollenberg I, Agua-Doce A, Hernandez A, et al. Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol. 2011;187:4553–4560.
70. Lim HW, Hillsamer P, Banham AH, et al. Cutting edge: direct suppression of B cells by CD4 + CD25+ regulatory T cells. J Immunol. 2005;175:4180–4183.
71. Chung Y, Tanaka S, Chu F, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med. 2011;17:983–988.
72. Gerner MY, Torabi-Parizi P, Germain RN. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. Immunity. 2015;42:172–185.
73. Sage PT, Alvarez D, Godec J, et al. Circulating T follicular regulatory and helper cells have memory-like properties. J Clin Invest. 2014;124:5191–5204.
74. Liu X, Chen X, Zhong B, et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature. 2014;507:513–518.
75. Vaeth M, Muller G, Stauss D, et al. Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression. J Exp Med. 2014;211:545–561.
76. Ray JP, Staron MM, Shyer JA, et al. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity. 2015;43:690–702.
77. Martinez GJ, Hu JK, Pereira RM, et al. Cutting edge: NFAT transcription factors promote the generation of follicular helper T cells in response to acute viral infection. J Immunol. 2016;196:2015–2019.
78. Serfling E, Berberich-Siebelt F, Chuvpilo S, et al. The role of NF-AT transcription factors in T cell activation and differentiation. Biochim Biophys Acta. 2000;1498:1–18.
79. Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011;34:932–946.
80. Sage P, Francisco L, Carman C, et al. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol. 2013;14:152–161.
81. Zhang R, Sage PT, Finn K, et al. B cells drive autoimmunity in mice with CD28-deficient regulatory T cells. J Immunol. 2017;199:3972–3980.
82. Aloulou M, Carr EJ, Gador M, et al. Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat Commun. 2016;7:10579.
83. Maceiras AR, Almeida SCP, Mariotti-Ferrandiz E, et al. T follicular helper and T follicular regulatory cells have different TCR specificity. Nat Commun. 2017;8:15067.
84. Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194:325–333.
85. Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007;56:1152–1163.
86. de Graav GN, Dieterich M, Hesselink DA, et al. Follicular T helper cells and humoral reactivity in kidney transplant patients. Clin Exp Immunol. 2015;180:329–340.
87. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58:652–662.
88. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant. 2013;13:3010–3020.
89. Landwehr-Kenzel S, Issa F, Luu SH, et al. Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells. Am J Transplant. 2014;14:594–606.
90. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int. 2008;21:728–741.
91. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int. 2008;21:742–754.
92. Linterman MA, Hill DL. Can follicular helper T cells be targeted to improve vaccine efficacy? F1000Research. 2016;5 (F1000 Faculty Rev):88–100.
93. Hu ZQ, Zhao WH. Critical role of PD-1/PD-L1 pathway in generation and function of follicular regulatory T cells. Cell Mol Immunol. 2013;10:286–288.
94. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–322.
95. Martin-Orozco N, Wang YH, Yagita H, et al. Cutting edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol. 2006;177:8291–8295.
96. Zhang Y, Chung Y, Bishop C, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A. 2006;103:11695–11700.
97. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
98. Ahmad SM, Martinenaite E, Holmström M, et al. The inhibitory checkpoint, PD-L2, is a target for effector T cells: novel possibilities for immune therapy. Oncoimmunology. 2018;7:e1390641.
99. Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–810.
100. Haynes NM, Allen CD, Lesley R, et al. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J Immunol. 2007;179:5099–5108.
101. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–3029.
102. Huss DJ, Mehta DS, Sharma A, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84–92.
103. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8:2086–2096.
104. Johnston RJ, Choi YS, Diamond JA, et al. STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med. 2012;209:243–250.
105. Ballesteros-Tato A, León B, Graf BA, et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity. 2012;36:847–856.
106. Botta D, Fuller MJ, Marquez-Lago TT, et al. Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection. Nat Immunol. 2017;18:1249–1260.
107. Leon B, Bradley JE, Lund FE, et al. FoxP3+ regulatory T cells promote influenza-specific Tfh responses by controlling IL-2 availability. Nat Commun. 2014;5:3495.
108. Sage PT, Sharpe AH. In vitro assay to sensitively measure T(FR) suppressive capacity and T(FH) stimulation of B cell responses. Methods Mol Biol. 2015;1291:151–160.
109. Shulman Z, Gitlin AD, Targ S, et al. T follicular helper cell dynamics in germinal centers. Science. 2013;341:673–677.
110. Kawamoto S, Tran TH, Maruya M, et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science. 2012;336:485–489.
111. Sage PT, Tan CL, Freeman GJ, et al. Defective TFH cell function and increased TFR cells contribute to defective antibody production in aging. Cell Rep. 2015;12:163–171.
112. Fonseca VR, Agua-Doce A, Maceiras AR, et al. Human blood Tfr cells are indicators of ongoing humoral activity not fully licensed with suppressive function. Sci Immunol. 2017;2:eaan1487.
113. Bentebibel SE, Lopez S, Obermoser G, et al. Induction of ICOS + CXCR3 + CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5:176ra32.
114. Abdulahad WH, Lepse N, Stegeman CA, et al. Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). Arthritis Res Ther. 2013;15:R70.
115. Le Coz C, Joublin A, Pasquali JL, et al. Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. PLoS One. 2013;8:e75319.
116. Ma J, Zhu C, Ma B, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol. 2012;2012:827480.
117. Zhu C, Ma J, Liu Y, et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 2012;97:943–950.
118. Simpson N, Gatenby P, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010;62:234–244.
119. Macdonald AJ, Cerosaletti K, Chen J, et al. OP0264 relative frequencies of circulating T follicular helper and T follicular regulatory cells in autoimmune patients and healthy control donors and the effect of disease modulating therapy. Ann Rheum Dis. 2016;75 (Suppl 2: EULAR 2016 meeting report).
120. Dhaeze T, Peelen E, Hombrouck A, et al. Circulating follicular regulatory T cells are defective in multiple sclerosis. J Immunol. 2015;195:832–840.
121. Morita R, Schmitt N, Bentebibel S, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34:108–121.
122. Wang L, Qiu J, Yu L, et al. Increased numbers of CD5 + CD19 + CD1dhighIL-10+ Bregs, CD4 + Foxp3+ Tregs, CD4 + CXCR5 + Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J Transl Med. 2014;12:251.
123. Cubas R, van Grevenynghe J, Wills S, et al. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection. J Immunol. 2015;195:5625–5636.
124. Miles B, Miller SM, Folkvord JM, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608.
125. Colineau L, Rouers A, Yamamoto T, et al. HIV-infected spleens present altered follicular helper T cell (Tfh) subsets and skewed B cell maturation. PLoS One. 2015;10:e0140978.
126. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144–4149.
127. Boswell KL, Paris R, Boritz E, et al. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. PLoS Pathog. 2014;10:e1003853.
128. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med. 2013;19:494–499.
129. Chen W, Bai J, Huang H, et al. Low proportion of follicular regulatory T cell in renal transplant patients with chronic antibody-mediated rejection. Sci Rep. 2017;7:1322.
130. Forcade E, Kim HT, Cutler C, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016;127:2489–2497.
131. Shi J, Luo F, Shi Q, et al. Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection. BMC Nephrol. 2015;16:182.
132. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant. 2014;14:59–69.
133. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4 + CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106:2903–2911.
134. Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123:3988–3998.
135. McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016;128:1013–1017.
136. Francis RS, Feng G, Tha-In T, et al. Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol. 2011;41:726–738.
137. Yoshizawa A, Ito A, Li Y, et al. The roles of CD25 + CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc. 2005;37:37–39.
138. Braza F, Dugast E, Panov I, et al. Central role of CD45RA- Foxp3hi memory regulatory T cells in clinical kidney transplantation tolerance. J Am Soc Nephrol. 2015;26:1795–1805.
139. Chenouard A, Chesneau M, Bui Nguyen L, et al. Renal operational tolerance is associated with a defect of blood Tfh cells that exhibit impaired B cell help. Am J Transplant. 2017;17:1490–1501.
140. O'Leary JG, Samaniego M, Barrio MC, et al. The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Transplantation. 2016;100:39–53.
141. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant. 2008;8:793–802.
142. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35:3332–3342.
143. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119:2052–2061.
144. Xu L, Huang Q, Wang H, et al. The kinase mTORC1 promotes the generation and suppressive function of follicular regulatory T cells. Immunity. 2017;47:538–551.e535.
145. Oh B, Yoon J, Farris A 3rd, et al. Rapamycin interferes with postdepletion regulatory T cell homeostasis and enhances DSA formation corrected by CTLA4-Ig. Am J Transplant. 2016;16:2612–2623.
146. Wang CJ, Heuts F, Ovcinnikovs V, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A. 2015;112:524–529.
147. Wing JB, Ise W, Kurosaki T, et al. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity. 2014;41:1013–1025.
148. Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest. 2014;124:4678–4680.
149. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest. 1994;93:424–428.
150. Laidlaw BJ, Lu Y, Amezquita RA, et al. Interleukin-10 from CD4+ follicular regulatory T cells promotes the germinal center response. Sci Immunol. 2017;2:pii: eaan4767.
151. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–547.
152. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–988.
153. Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–1416.
154. Paterson AM, Lovitch SB, Sage PT, et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med. 2015;212:1603–1621.
155. Sage PT, Paterson AM, Lovitch SB, et al. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity. 2014;41:1026–1039.
156. Cohen JB, Eddinger KC, Forde KA, et al. Belatacept compared with tacrolimus for kidney transplantation: a propensity score matched cohort study. Transplantation. 2017;101:2582–2589.
157. Del Bello A, Marion O, Milongo D, et al. Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients. Expert Rev Clin Pharmacol. 2016;9:215–227.
158. Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77:1221–1233.
159. Kumar D, LeCorchick S, Gupta G. Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne). 2017;4:60.
160. Kim I, Wu G, Chai NN, et al. Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. Transpl Immunol. 2016;38:84–92.
161. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–343.
162. de Graav GN, Hesselink DA, Dieterich M, et al. Belatacept does not inhibit follicular T cell-dependent B-cell differentiation in kidney transplantation. Front Immunol. 2017;8:641.
163. Streitz M, Miloud T, Kapinsky M, et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res. 2013;2:17.
164. Rossetti M, Spreafico R, Saidin S, et al. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J Immunol. 2015;194:113–124.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.